Business Wire

Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform

Del

For people either living with or caring for people with diabetes, Glooko and Diasend are well-known for making diabetes management easier by offering best-in-class diabetes management and analytics platforms that facilitate data driven care for patients and clinicians. In a move that will accelerate the overarching mission to make diabetes management easier worldwide, Glooko and Diasend today announced they have merged into a unified company.

“This is a big day for us – we are thrilled to come together to be able to deliver products and services that will offer even more value to patients and healthcare providers around the world,” says Rick Altinger, CEO of Glooko, Inc.

“This is without a doubt the best possible scenario for our two companies, as well as for patients and the care teams that serve them. From our standpoint, this means adding even more functionality to an already very strong technical platform,” says Anders Sonesson, CEO of Diasend AB.

As a combined entity, the new company now serves 4,000 diabetes clinics in 23 countries across 15 languages, impacting tens of millions of people with diabetes. The joint platform downloads data from more than 160 different devices – including glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers, in total covering over 95% of diabetes devices used worldwide. Together the joint solution enables support for people with diabetes during and in-between doctor visits, as well as in-office diabetes data uploads and analytics. The products also provide smartphone enabled self-management and a population health platform that supports diabetes coaches around the world.

The two companies, which have chosen to unite under the Glooko name, have recently raised $8M in equity financing, led by global venture capital firm Canaan Partners, to accelerate integration and sales efforts. Other investors include Social Capital, Samsung Ventures and Yogen Dalal, Glooko’s founder and partner emeritus at venture capital firm Mayfield fund.

Glooko, based in Mountain View, CA and Diasend, in Gothenburg, Sweden, have both spent recent years perfecting their respective take on the optimal solution for diabetes data management. Recent product announcements show this. Glooko’s recently announced Glooko Advise product line is focused on leveraging diabetes data to deliver personalized medicine recommendations to patients and care teams. Diasend’s recent announcement focused on enabling Abbott’s Freestyle LibreLink patients to see their glucose data alongside pump data. As a combined entity, these and other product delivery initiatives will not only continue, but will also be optimized and accelerated through the larger combined team.

About Diasend

Diasend simplifies life for people with diabetes and facilitates the work of their health care providers by optimizing diabetes data management. The company’s comprehensive and market leading solution involves transmitting, storing and analyzing data from more than 140 different glucose meters, insulin pumps, CGM systems and leading activity trackers – allowing patients and caregivers to easily access the exact same information. Diasend’s products and services, all FDA approved and CE marked, are currently used in 23 countries. Headquarters are located in Gothenburg, Sweden – with subsidiaries in Chicago and London. For more information, please visit www.diasend.com

About Glooko

Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and insightful reports, graphs and risk flags to health systems and payers. Learn more at http://www.glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.

Contact information

Glooko
Michelle de Haaff
Vice President of Marketing and Customer Success
michelle@glooko.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Exclusive Group Adds Mellanox to BigTec Portfolio19.10.2017 08:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it has struck a major distribution agreement with Mellanox Technologies to add the market-leading vendor’s datacentre interconnect solutions to the global BigTec portfolio. The deal, which sees Mellanox and BigTec team up in 24 countries across EMEA and APAC, brings global expansion opportunities to both parties as well as hundreds of reseller partners, providing the ideal complement to storage and hyper-converged solutions from fellow BigTec vendors including Nutanix and Rubrik. “Mellanox has a unique and comprehensive technology offering that reflects both its commitment to open standards in networking and cloud computing, and its hunger to continually disrupt the datacentre market,” said Martin Bichler, Group Vendor Manager, BigTec. “This is yet another bonus for BigTec specialist resellers and

More Firms Select Duco for Mandatory MiFID II Reconciliation19.10.2017 07:01Pressemelding

Duco, the global provider of self-service data normalization and reconciliation services, today announced that a further three firms will be using Duco Cube, the company’s flagship reconciliation solution, for MiFID II reporting reconciliation. The firms include Redburn, Europe’s largest independent equities broker, and two global banks. Ranith de Silva, Operations Manager at Redburn, said: “MiFID II transaction data needs to undergo a number of enrichment processes between front office capture and the final report, which need to be replicated in the reconciliation process, covering large complex data sets. The quick deployment, flexibility and usability of Duco's self-service application enables us to efficiently build towards this reconciliation process with very little technical support.” Regular reconciliation is a mandatory requirement under MiFID II. The firms w

SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network19.10.2017 07:00Pressemelding

SIAE MICROELETTRONICA announces the successful deployment of iVeritas in Telefónica Deutschland's mobile backhaul as part of the TST project. Telefónica Deutschland Transport SDN Trial (TST), is a project whose long-term aim is offering value added services on future 5G network infrastructure in an SDN environment. As part of this project SIAE MICROELETTRONICA, a Telefónica long term supplier of wireless technology, deployed its new SDN application named iVeritas offering multivendor performance analytics and preventive maintenance analysis. iVeritas sits on top of the OpenDaylight transport SDN controller that through an SDN mediator interfaces to existing SNMP microwave links, the selected portion of the network was composed by links from three different vendors. iVeritas collected performance information from the links, correlating the data and presenting them acco

Rimini Street Expands Investment and Operations in Europe18.10.2017 22:00Pressemelding

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43Pressemelding

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15Pressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom